



**Media Contact:**

Karen Frey  
Strategic Communications  
(916) 939-3757  
kfrey@strategiccom.biz

**Nextrials Introduces Prism 2.7 EDC Solution to Deliver  
Accurate Data More Quickly to Biotechnology, Medical Device,  
and Pharmaceutical Companies**

*Nextrials Prism 2.7 Features Superior Ease-of-Use and Adaptive Design to  
Handle Even the Most Complex Clinical Trials*

**SAN RAMON, Calif. – October 27, 2003** – Nextrials, Inc. today introduced Prism 2.7, the newest version of its Electronic Data Capture (EDC) solution designed to accelerate clinical study start-up time, deliver more accurate data and ensure clear, well-defined results for biotechnology, medical device and pharmaceutical companies. Successfully combining its extensive clinical research and data management experience for the creation of a superior clinical trial EDC solution, Nextrials has delivered in Prism 2.7 a solution--available today--that will help life science companies allocate resources more efficiently and bring life-enhancing products to market faster.

“With our newly-enhanced Prism EDC software, we believe we’ve successfully answered the market need for a robust, fully integrated, user-friendly EDC solution,” says Jim Rogers, co-founder and president of Nextrials, Inc. “Since our company inception in 1999,

our goal has been to enhance our customers' ability to conduct significant, complex clinical trials with easy-to-use, integrated technology. Our technology solutions, created and implemented from the ground up by experienced clinical research professionals, are designed to accelerate clinical trials and help deliver life saving products to people more quickly.”

According to Rogers, Nextrials Prism 2.7 is focused on ease-of-use with an intuitive interface, so that all users have an exceptional experience using Prism. “Clinical sites are key end users when implementing an EDC study, and Prism is highly regarded by clinical site staff,” Rogers says. “In a recent customer survey conducted by one of our key clients, 90 percent of Prism users were pleased with our software, 10 percent were neutral and no users were dissatisfied.”

### ***Nextrials' Prism 2.7 Significantly Improves Clinical Trial Data-Capture Process***

Nextrials recently enhanced its product offerings with the launch of Nextrials Prism 2.7. Prism eliminates delays in start-up and misinformation of ongoing data; eliminates confusion and delays in analysis; facilitates patient enrollment and reduces the burden of data clean-up.

Nextrials' Prism 2.7 adds a comprehensive lab data management system and enhanced data visualization to an established product. These new features integrate into a single interface with the most innovative features in the industry including dynamic data quality management, interactive subject screening and randomization, integrated product safety tracking, adaptive study design, real-time project management status alerts, business intelligence functionality, flexible inventory management and sophisticated access control. The robust features ensure Prism can handle the most complex trials, including oncology and

transplant studies. All of this is provided to clinical sites and biopharmaceutical companies through secure access to Nextrials web-based servers. Users need only a computer, browser and an Internet connection to run Prism.

“The prompt securing of clinical datasets that are 100 percent complete and correct is of paramount priority; we can count on that using Nextrials’ Prism solution,” says Dan Walczak, director of research for the National Marrow Donor Program. “With Nextrials, we are confident that they can facilitate getting our critical research initiatives completed quickly and cleanly.”

### ***Bay Area Headquarters Provides Clinical Research, Technology Expertise to Biotech Hub***

Headquartered in the San Francisco Bay Area, Nextrials is the only EDC software and services company located in the world’s center for biotechnology. This important advantage allows Nextrials to provide higher quality service to the large number of sponsors in the surrounding area.

Nextrials executives have led the way in developing and implementing industry standards to streamline the clinical trial process. The company founders include former researchers from Genentech's oncology department who were pivotal in helping bring to market Herceptin™, a revolutionary biologic for breast cancer. Based on this and other clinical trial experiences, Nextrials was founded and Prism was developed. Nextrials has partnered on highly complex cancer trials with organizations such as Genentech, Novacea, Biomira and the National Marrow Donor Program.

**About Nextrials**

Nextrials, through its origins in clinical research and data management offers the industry's most innovative and easy-to-use Electronic Data Capture (EDC) solution, Prism. Prism smoothes the transition to EDC to help biotechnology, pharmaceutical and medical device companies effectively allocate resources and bring life-saving drugs to market quicker. Because of its superior ease-of-use, adaptive design, integrated safety monitoring and reporting features, Prism can handle the most complex trials, including oncology and transplant studies.

Nextrials is headquartered in the San Francisco Bay Area. Additional information about the company is available at: [www.nextrials.com](http://www.nextrials.com) or by contacting company officials directly at: Nextrials; 5000 Executive Parkway, Suite 540; San Ramon, California 94583. Phone: (925) 355-3000.

# # #